Results 1 to 10 of about 2,109,380 (161)
Einstein (São Paulo), 2004 We describe a patient with a prolonged aPTT who was diagnosedas having factor XI deficiency after a rather large hematoma wasformed after angiography.
Jayme Diamant +4 more
doaj +5 more sources
Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives
Romanian Journal of Internal Medicine, 2023 Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action ...
Vlădăreanu Ana-Maria, Roşca Adrian
doaj +3 more sources
XI before X: The Promise of Factor XI Inhibitors [PDF]
Kidney International ReportsJeffrey I. Weitz, Husam Alzayer
doaj +4 more sources
Case Report: Allelic and biallelic variants in coagulation factor XI cause factor XI deficiency [PDF]
Frontiers in Cardiovascular MedicineFactor XI deficiency is a rare inherited coagulation disorder with an estimated prevalence of affecting 1 in 1 million. It is characterized by mild and variable bleeding phenotypes, including bruises, nosebleeds, hematuria, and postpartum hemorrhage.
Chen Liang +9 more
doaj +2 more sources
Factor XI and XII inhibitors–Dawn of a new era [PDF]
Indian Heart JournalThe history of coagulation cascade dates back to 17th century. The extrinsic and intrinsic pathways were proposed in 1998. Extrinsic pathway includes the tissue factor and stable factor which activates factor X and with help of factor V, this converts ...
Chhabi Satpathy +2 more
doaj +2 more sources
Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Novel anticoagulants targeting coagulation factor (F)XI/activated FXI (FXIa) are currently under development. However, whether FXI is present in human deep vein thrombosis (DVT) and whether FXIa and activated FX (FXa) play different roles in ...
Nobuyuki Oguri +12 more
doaj +2 more sources
Identifying the silent deficiency: Severe Factor XI deficiency in an asymptomatic patient with isolated prolonged activated partial thromboplastin time—A case report [PDF]
SAGE Open Medical Case ReportsAssessing a patient with a suspected bleeding disorder is a complex aspect of hematology. Prolonged activated partial thromboplastin time often indicates a coagulation factor deficiency or inhibitor and warrants detailed evaluation. Factor XI deficiency,
Awni Alshurafa +4 more
doaj +2 more sources
Targeting factor XI as a compromise between thrombosis and bleeding [PDF]
Cardiology JournalThromboembolic diseases have long been a leading cause of morbidity and mortality, necessitating advances in anticoagulant drugs. Heparins, vitamin K inhibitors, and direct oral anticoagulants (DOACs) are well-established drug classes that help prevent ...
Aleksandra Żuk-Łapan +6 more
doaj +2 more sources
Acta Médica Portuguesa, 2007 Factor XI deficiency is a rare bleeding disorder in general population, sometimes it can only become clinically evident when patients develop abnormal bleeding after elective surgery. The authors report a clinical case of a 59 year-old woman who after 10
Pedro Conde, Ana Alegria, Andrade Moniz
doaj +3 more sources
Inhibition of Factor XI Using RBD4059 [PDF]
JACC: Basic to Translational ScienceSummary: Coagulation factor XI (FXI) is an attractive target for novel antithrombotic drugs because of its minor role in hemostasis, which may address the current unmet medical need regarding a powerful anticoagulant with low bleeding risk.
Junshi Liang, MSc +13 more
doaj +2 more sources